Verapamil stereoisomers induce antiproliferative effects in vascular smooth muscle cells via autophagy

Toxicology and Applied Pharmacology

Volumn 262, Issue 3, 2012, Pages 265-272

  Salabei, Joshua K ^a   Balakumaran, Arun ^d,e   Frey, Justin C ^c,f   Boor, Paul J ^d   Treinen Moslen, Mary ^d   Conklin, Daniel J ^a,b,c,d  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF WISCONSIN EAU CLAIRE   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e NONE   (United States)

^f MERCY HEALTH SYSTEM   (United States)

Author keywords

Autophagosome; Calcium channel blockers; Diltiazem; LC3 conversion; Mitophagy; MTT assay; Proliferation; Restenosis; Smooth muscle cell

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DILTIAZEM; THYMIDINE DERIVATIVE; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL DENSITY; CELL PROLIFERATION; CELL STRUCTURE; CELL VACUOLE; CELL VIABILITY; CONTROLLED STUDY; LYSOSOME; MITOCHONDRION; NEWBORN; NONHUMAN; RAT; SMOOTH MUSCLE FIBER; STEREOISOMERISM; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

RATTUS;

EID: 84863839690     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.04.036     Document Type: Article

References (42)

1. 2+ channel blockers verapamil and nifedipine inhibit apoptosis induced by 25-hydroxycholesterol in human aortic smooth muscle cells. J. Lipid Res. 1997, 38:2049-2061.
2. Armstrong M.L., Heistad D.D., Lopez J.A. Regression of atherosclerosis. A role for calcium antagonists. Am. J. Hypertens. 1991, 4:503S-511S.
3. Atkinson J.B. Accelerated arteriosclerosis after transplantation: the possible role of calcium channel blockers. Int. J. Cardiol. 1997, 62(Suppl. 2):S125-S134.
4. Bahro M., Pfeifer U. Short-term stimulation by propranolol and verapamil of cardiac cellular autophagy. J. Mol. Cell. Cardiol. 1987, 19:1169-1178.
5. Balakumaran A., Campbell G.A., Moslen M.T. Calcium channel blockers induce thymic apoptosis in vivo in rats. Toxicol. Appl. Pharmacol. 1996, 139:122-127.
6. Bernas T., Dobrucki J.W. The role of plasma membrane in bioreduction of two tetrazolium salts, MTT, and CTC. Arch. Biochem. Biophys. 2000, 380:108-116.
7. Bernas T., Dobrucki J. Mitochondrial and nonmitochondrial reduction of MTT: interaction of MTT with TMRE, JC-1, and NAO mitochondrial fluorescent probes. Cytometry 2002, 47:236-242.
8. 2+-calpain and caspase-3 dependent pathway. Pharmacol. Res. 2003, 48:571-578.
9. Collier A.C., Pritsos C.A. The mitochondrial uncoupler dicumarol disrupts the MTT assay. Biochem. Pharmacol. 2003, 66:281-287.
10. Conklin D.J., Langford S.D., Boor P.J. Contribution of serum and cellular semicarbazide-sensitive amine oxidase to amine metabolism and cardiovascular toxicity. Toxicol. Sci. 1998, 46:386-392.
11. Corsini A., Bonfatti M., Quarato P., Accomazzo M.R., Raiteri M., Sartani A., Testa R., Nicosia S., Paoletti R., Fumagalli R. Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J. Cardiovasc. Pharmacol. 1996, 28:687-694.
12. Eickelberg O., Roth M., Mussmann R., Rudiger J.J., Tamm M., Perruchoud A.P., Block L.H. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-kappaB in primary human vascular smooth muscle cells. Circulation 1999, 99:2276-2282.
13. Henry P.D. Atherogenesis, calcium and calcium antagonists. Am. J. Cardiol. 1990, 66:3I-6I.
14. Henry P.D. Antiperoxidative actions of calcium antagonists and atherogenesis. J. Cardiovasc. Pharmacol. 1991, 18(Suppl. 1):S6-S10.
15. Jones P.A., Scott-Burden T., Gevers W. Glycoprotein, elastin, and collagen secretion by rat smooth muscle cells. Proc. Natl. Acad. Sci. 1979, 76:353-357.
16. Jukema J.W., van der Hoorn J.W. Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Expert. Opin. Pharmacother. 2004, 5:459-468.
17. Kauder W.F., Watts J.A. Antioxidant properties of dihydropyridines in isolated rat hearts. Biochem. Pharmacol. 1996, 51:811-819.
18. Klionsky D.J. Protocols, toolboxes and resource papers. Autophagy 2012, 8.
19. Ko Y., Totzke G., Graack G.H., Heidgen F.J., Meyer zu Brickwedde M.K., Dusing R., Vetter H., Sachinidis A. Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells. J. Hypertens. 1993, 11:1171-1178.
20. Lai Y.M., Fukuda N., Su J.Z., Suzuki R., Ikeda Y., Takagi H., Tahira Y., Kanmatsuse K. Novel mechanisms of the antiproliferative effects of amlodipine in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertens. Res. 2002, 25:109-115.
21. Lemay J., Tea B.S., Hamet P., deBlois D. Regression of neointimal lesions in the carotid artery of nifedipine-treated SHR and WKY rats: possible role of apoptosis. J. Vasc. Res. 2001, 38:462-470.
22. Li W., Li J., Liu W., Altura B.T., Altura B.M. Alcohol-induced apoptosis of canine cerebral vascular smooth muscle cells: role of extracellular and intracellular calcium ions. Neurosci. Lett. 2004, 354:221-224.
23. Marche P., Stepien O. Calcium antagonists and vascular smooth muscle cell reactivity. Z. Kardiol. 2000, 89(Suppl. 2):140-144.
24. Martinet W., Verheye S., De Meyer G.R. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 2007, 3:241-244.
25. Mitsuyoshi H., Nakashima T., Sumida Y., Yoh T., Nakajima Y., Ishikawa H., Inaba K., Sakamoto Y., Okanoue T., Kashima K. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem. Biophys. Res. Commun. 1999, 263:537-542.
26. Mizushima N., Kuma A., Kobayashi Y., Yamamoto A., Matsubae M., Takao T., Natsume T., Ohsumi Y., Yoshimori T. Mouse Apg16L, a novel WD-repeat protein, targets to the autophagic isolation membrane with the Apg12-Apg5 conjugate. J. Cell Sci. 2003, 116:1679-1688.
27. Munro E., Patel M., Chan P., Betteridge L., Gallagher K., Schachter M., Wolfe J., Sever P. Effect of calcium channel blockers on the growth of human vascular smooth muscle cells derived from saphenous vein and vascular graft stenoses. J. Cardiovasc. Pharmacol. 1994, 23:779-784.
28. Patel M.K., Chan P., Betteridge L.J., Schachter M., Sever P.S. Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol. J. Cardiovasc. Pharmacol. 1995, 25:652-657.
29. Puscas L., Gilau L., Coltau M., Pasca R., Domuta G., Baican M., Hecht A. Calcium channel blockers reduce blood pressure in part by inhibiting vascular smooth muscle carbonic anhydrase I. Cardiovasc. Drugs Ther. 2000, 14:523-528.
30. Sawada H., Takami K., Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 2005, 83:282-292.
31. Schachter M. Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers. Int. J. Cardiol. 1997, 62(Suppl. 2):S85-S90.
32. 2+ channel blockers. Atherosclerosis 1991, 88:109-132.
33. Schroeder J.S., Gao S.Z. Calcium blockers and atherosclerosis: lessons from the Stanford Transplant Coronary Artery Disease/Diltiazem Trial. Can. J. Cardiol. 1995, 11:710-715.
34. Timar J., Chopra H., Rong X., Hatfield J.S., Fligiel S.E., Onoda J.M., Taylor J.D., Honn K.V. Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation. J. Cancer Res. Clin. Oncol. 1992, 118:425-434.
35. Tulenko T.N., Laury-Kleintop L., Walter M.F., Mason R.P. Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection?. Int. J. Cardiol. 1997, 62(Suppl. 2):S55-S66.
36. Waters D., Lesperance J. Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world. Am. Heart J. 1994, 128:1309-1316.
37. Weibel E.R. Stereological principles for morphometry in electron microscopic cytology. Int. Rev. Cytol. 1969, 26:235-302.
38. Weir M.R., Peppler R., Gomolka D., Handwerger B.S. Evidence that the antiproliferative effect of verapamil on afferent and efferent immune responses is independent of calcium channel inhibition. Transplantation 1992, 54:681-685.
39. Weir M.R., Gomolka D., Peppler R., Handwerger B.S. Mechanisms responsible for inhibition of lymphocyte activation by agents which block membrane calcium or potassium channels. Transplant. Proc. 1993, 25:605-609.
40. Weir M.R., Peppler R., Gomolka D., Handwerger B.S. Calcium channel blockers inhibit cellular uptake of thymidine, uridine and leucine: the incorporation of these molecules into DNA, RNA and protein in the presence of calcium channel blockers is not a valid measure of lymphocyte activation. Immunopharmacology 1993, 25:75-82.
41. 2+ channel interaction. Trends Pharmacol. Sci. 1990, 11:38-44.
42. Zhang Y.Z., Gao P.J., Wang X.Y., Stepien O., Marche P., Zhang Z.L., Zhu D.L. The inhibitory mechanisms of amlodipine in human vascular smooth muscle cell proliferation. Hypertens. Res. 2000, 23:403-406.